Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

NCT04353765 · clinicaltrials.gov ↗

COMPLETED

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib monotherapy
DRUG: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC

Sponsor

Ipsen